However, more recent randomized placebo-controlled clinical trials failed to prove a significant benefit of treatment with β-AR agonists with respect to clinical outcome or mortality in patients with ALI or ARDS. This evidence concerns the gene ADRB2 and acute respiratory distress syndrome.